Lantheus Holdings Inc. (LNTH) Sets New 12-Month High at $8.58
Lantheus Holdings Inc. (NASDAQ:LNTH) reached a new 52-week high on Monday . The stock traded as high as $8.58 and last traded at $8.33, with a volume of 452,374 shares. The stock had previously closed at $7.89.
Several research firms have recently weighed in on LNTH. Zacks Investment Research upgraded shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $7.00 price objective for the company in a research report on Monday, August 8th. Jefferies Group reiterated a “buy” rating on shares of Lantheus Holdings in a research report on Friday, August 5th. Finally, Credit Suisse Group AG set a $4.00 price objective on shares of Lantheus Holdings and gave the stock a “hold” rating in a research report on Friday, August 5th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $5.80.
The company has a market capitalization of $224.26 million and a price-to-earnings ratio of 8.33. The company has a 50 day moving average price of $5.24 and a 200-day moving average price of $3.01.
Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.18. The company earned $78 million during the quarter, compared to analysts’ expectations of $72.66 million. On average, equities analysts predict that Lantheus Holdings Inc. will post $0.54 EPS for the current fiscal year.
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.